Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.00M$7.00Mderived— vs Q4 2024 Net Income-$54.89M-$54.89MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$60,631,000N/M Operating Cash Flowderived-$44,865,000N/M Free Cash Flowderived-$44,866,000N/M Margins · derivedOperating margin-866.3%
Net margin-784.3%
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end